Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta‐analysis

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1... INTRODUCTIONHepatitis C virus (HCV) infection remains a serious public health issue worldwide. About 55‐85% of the population who have contact with HCV can develop chronic infection, which can lead to liver cirrhosis and furthermore hepatocellular carcinoma. Approximately, 130‐150 million people are affected globally and 700 000 people die each year due to HCV‐related liver complications. There are seven major genotypes, and more than 100 subtypes, of HCV from which genotype 1 is the most prevalent HCV type globally and responsible for about 60% of infections.Until recently, IFN‐based regimens were used to treat HCV, but these therapeutic regimens have been known to cause severe adverse events (AEs) and treatment discontinuation. Moreover, these regimens require weekly injection or complex dosing which can reduce the patients’ compliance. Recently, new direct‐acting antivirals (DAAs) with different mechanisms of action have been developed to provides much more efficacious and better‐tolerated therapeutic strategies than the older regimens. They can be used in combination with interferon (IFN) in shorter regimens or in combination with other DAAs in IFN‐free regimens to overcome the disadvantages of concomitant IFNs. Several IFN‐free regimens have been recommended by the World Health Organization (WHO), such as the combination of daclatasvir (DCV) and sofosbuvir (SOF) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Medical Virology Wiley

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta‐analysis

Loading next page...
 
/lp/wiley/beclabuvir-in-combination-with-asunaprevir-and-daclatasvir-for-Y9EGk8Y8pc
Publisher
Wiley
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0146-6615
eISSN
1096-9071
D.O.I.
10.1002/jmv.24947
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONHepatitis C virus (HCV) infection remains a serious public health issue worldwide. About 55‐85% of the population who have contact with HCV can develop chronic infection, which can lead to liver cirrhosis and furthermore hepatocellular carcinoma. Approximately, 130‐150 million people are affected globally and 700 000 people die each year due to HCV‐related liver complications. There are seven major genotypes, and more than 100 subtypes, of HCV from which genotype 1 is the most prevalent HCV type globally and responsible for about 60% of infections.Until recently, IFN‐based regimens were used to treat HCV, but these therapeutic regimens have been known to cause severe adverse events (AEs) and treatment discontinuation. Moreover, these regimens require weekly injection or complex dosing which can reduce the patients’ compliance. Recently, new direct‐acting antivirals (DAAs) with different mechanisms of action have been developed to provides much more efficacious and better‐tolerated therapeutic strategies than the older regimens. They can be used in combination with interferon (IFN) in shorter regimens or in combination with other DAAs in IFN‐free regimens to overcome the disadvantages of concomitant IFNs. Several IFN‐free regimens have been recommended by the World Health Organization (WHO), such as the combination of daclatasvir (DCV) and sofosbuvir (SOF)

Journal

Journal of Medical VirologyWiley

Published: Jan 1, 2018

Keywords: ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off